The commercial availability of Nitisinone Capsules represents a significant milestone for Eton Pharmaceuticals, potentially opening up a new revenue stream. Given the company's projection of the market exceeding $50M annually, this launch could have a positive impact on ETON's financial performance in the short term. The specificity of the product to an ultra-rare disease also highlights ETON's strategic focus on niche markets, which could attract investor interest.